Christopher Koh, M.D. M.H.Sc.

Photo of Dr. Christopher Koh
Scientific Focus Areas: Clinical Research, Genetics and Genomics, Immunology, Microbiology and Infectious Diseases, Virology


A selection of recent and significant publications can be viewed below.

Spleen and Liver Volumetrics as Surrogate Markers of Hepatic Venous Pressure Gradient in Patients With Noncirrhotic Portal Hypertension.
Etzion O, Takyar V, Novack V, Gharib AM, Canales R, Adebogun A, Matsumoto E, Eccleston JL, Kleiner DE, Rosenzweig SD, Gunay-Aygun M, Uzel G, Fuss I, Childs R, Holland SM, Levy EB, Liang TJ, Heller T, Koh C.
Hepatol Commun (2018 Aug) 2:919-928. Abstract/Full Text
Association of Hepatic Steatosis With Subclinical Atherosclerosis: Systematic Review and Meta-Analysis.
Kapuria D, Takyar VK, Etzion O, Surana P, O'Keefe JH, Koh C.
Hepatol Commun (2018 Aug) 2:873-883. Abstract/Full Text
Liver disease in patients with cystic fibrosis.
Kamal N, Surana P, Koh C.
Curr Opin Gastroenterol (2018 May) 34:146-151. Abstract/Full Text
Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
Yurdaydin C, Keskin O, Kalkan Ç, Karakaya F, Çalişkan A, Karatayli E, Karatayli S, Bozdayi AM, Koh C, Heller T, Idilman R, Glenn JS.
Hepatology (2018 Apr) 67:1224-1236. Abstract/Full Text
Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity.
Koh C, Sakiani S, Surana P, Zhao X, Eccleston J, Kleiner DE, Herion D, Liang TJ, Hoofnagle JH, Chernick M, Heller T.
Hepatology (2017 Aug) 66:591-601. Abstract/Full Text
Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.
Canini L, Koh C, Cotler SJ, Uprichard SL, Winters MA, Han MAT, Kleiner DE, Idilman R, Yurdaydin C, Glenn JS, Heller T, Dahari H.
Hepatol Commun (2017 Jun) 1:288-292. Abstract/Full Text
Complications of percutaneous liver biopsy with Klatskin needles: a 36-year single-centre experience.
Takyar V, Etzion O, Heller T, Kleiner DE, Rotman Y, Ghany MG, Fryzek N, Williams VH, Rivera E, Auh S, Liang TJ, Hoofnagle JH, Koh C.
Aliment Pharmacol Ther (2017 Mar) 45:744-753. Abstract/Full Text
Noninvasive markers for staging fibrosis in chronic delta hepatitis.
Takyar V, Surana P, Kleiner DE, Wilkins K, Hoofnagle JH, Liang TJ, Heller T, Koh C.
Aliment Pharmacol Ther (2017 Jan) 45:127-138. Abstract/Full Text
Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant.
Li J, Woods SL, Healey S, Beesley J, Chen X, Lee JS, Sivakumaran H, Wayte N, Nones K, Waterfall JJ, Pearson J, Patch AM, Senz J, Ferreira MA, Kaurah P, Mackenzie R, Heravi-Moussavi A, Hansford S, Lannagan TRM, Spurdle AB, Simpson PT, da Silva L, Lakhani SR, Clouston AD, Bettington M, Grimpen F, Busuttil RA, Di Costanzo N, Boussioutas A, Jeanjean M, Chong G, Fabre A, Olschwang S, Faulkner GJ, Bellos E, Coin L, Rioux K, Bathe OF, Wen X, Martin HC, Neklason DW, Davis SR, Walker RL, Calzone KA, Avital I, Heller T, Koh C, Pineda M, Rudloff U, Quezado M, Pichurin PN, Hulick PJ, Weissman SM, Newlin A, Rubinstein WS, Sampson JE, Hamman K, Goldgar D, Poplawski N, Phillips K, Schofield L, Armstrong J, Kiraly-Borri C, Suthers GK, Huntsman DG, Foulkes WD, Carneiro F, Lindor NM, Edwards SL, French JD, Waddell N, Meltzer PS, Worthley DL, Schrader KA, Chenevix-Trench G.
Am J Hum Genet (2016 May 5) 98:830-842. Abstract/Full Text
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T.
Lancet Infect Dis (2015 Oct) 15:1167-1174. Abstract/Full Text
Liver injury is associated with mortality in sickle cell disease.
Feld JJ, Kato GJ, Koh C, Shields T, Hildesheim M, Kleiner DE, Taylor JG 6th, Sandler NG, Douek D, Haynes-Williams V, Nichols JS, Hoofnagle JH, Jake Liang T, Gladwin MT, Heller T.
Aliment Pharmacol Ther (2015 Oct) 42:912-21. Abstract/Full Text
Understanding the presence of false-positive antibodies in acute hepatitis.
Sakiani S, Koh C, Heller T.
J Infect Dis (2014 Dec 15) 210:1886-9. Abstract/Full Text
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.
Guedj J, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, Haynes-Williams V, Liang TJ, Hoofnagle JH, Heller T, Dahari H.
Hepatology (2014 Dec) 60:1902-10. Abstract/Full Text
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.
Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, Schickel JN, Tran DQ, Stoddard J, Zhang Y, Frucht DM, Dumitriu B, Scheinberg P, Folio LR, Frein CA, Price S, Koh C, Heller T, Seroogy CM, Huttenlocher A, Rao VK, Su HC, Kleiner D, Notarangelo LD, Rampertaap Y, Olivier KN, McElwee J, Hughes J, Pittaluga S, Oliveira JB, Meffre E, Fleisher TA, Holland SM, Lenardo MJ, Tangye SG, Uzel G.
Science (2014 Sep 26) 345:1623-1627. Abstract/Full Text
Long-term therapy of chronic delta hepatitis with peginterferon alfa.
Heller T, Rotman Y, Koh C, Clark S, Haynes-Williams V, Chang R, McBurney R, Schmid P, Albrecht J, Kleiner DE, Ghany MG, Liang TJ, Hoofnagle JH.
Aliment Pharmacol Ther (2014 Jul) 40:93-104. Abstract/Full Text
What is the future of ribavirin therapy for hepatitis C?
Koh C, Liang TJ.
Antiviral Res (2014 Apr) 104:34-9. Abstract/Full Text
AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations.
Koh C, Zhao X, Samala N, Sakiani S, Liang TJ, Talwalkar JA.
Hepatology (2013 Dec) 58:2142-52. Abstract/Full Text
Liver stiffness increases acutely during sickle cell vaso-occlusive crisis.
Koh C, Turner T, Zhao X, Minniti CP, Feld JJ, Simpson J, Demino M, Conrey AK, Jackson MJ, Seamon C, Kleiner DE, Kato GJ, Heller T.
Am J Hematol (2013 Nov) 88:E250-4. Abstract/Full Text
Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy.
Koh C, Heller T, Haynes-Williams V, Hara K, Zhao X, Feld JJ, Kleiner DE, Rotman Y, Ghany MG, Liang TJ, Hoofnagle JH.
Aliment Pharmacol Ther (2013 May) 37:887-94. Abstract/Full Text